Composition for reducing injury caused by uv radiation

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents composition for reducing injury caused by ultraviolet radiation, which includes one or more compounds selected from the group consisting of D-methionine and its salts.

EFFECT: invention provides creation of stable and safe composition, which can be applied daily.

10 cl, 37 ex, 7 dwg

 

The technical field to which the invention relates

The present invention relates to compositions for reducing damage caused by ultraviolet radiation comprising one or more compounds selected from the group consisting of methionine and D-serine, as well as their derivatives and/or salts, to a method of improving the condition and disease of the skin caused by ultraviolet radiation, and cosmetic skin conditions, including the stage of introduction of one or more compounds selected from the group consisting of methionine and D-serine, as well as their derivatives and/or salts.

The level of technology

Ultraviolet radiation is divided into long-wavelength region of the ultraviolet radiation with a wavelength of more than about 320 nm (UV-A), medium-wave region of the ultraviolet radiation from about 320 to about 280 nm (UV-B) and the wavelength region of ultraviolet radiation with a wavelength of less than approximately 280 nm (UV-C). Among the above, the UV-C is not contained in sunlight reaching the earth because it absorbs the ozone layer. Although UV-A and UV-B are contained in sunlight reaching the earth, UV-B is partially absorbed by the ozone layer. However, as UV-A is not absorbed by the ozone layer, it prevails in ultraviolet radiation, temperature is the face of the earth, and causes damage to the skin.

In non-Patent literature 1 discloses a disease involving ultraviolet radiation, including wrinkles, erythema, pigmentary xeroderma, chronic actinic dermatitis, squamous cell carcinoma, basal cell carcinoma, malignant melanoma, Bowen's disease, solar keratosis, photodermatosis, light smallpox and photodermatitis, whereas in non-Patent literature 2 as examples are solar dermatitis, chronic actinic dermatopathia, actinic keratosis, actinic cheilitis, syndrome favr-Rokusho, photodermatosis, photodermatol, breakaway dermatitis, photosensitive drug rash, polymorphic light rash, light smallpox, solar urticaria, chronic photosensitive dermatitis, xeroderma pigmentosum, freckles, porphyria, pellagra, a disease of Hartnup, solar keratosis, dermatomyositis, lichen planus, disease Daria, red hairy pytilias, rosacea, atopic dermatitis, chloasma, herpes simplex and lupus erythematosus.

The documents of the prior art

Non-patent documents

Non-patent document 1: "HIFUSHIKKAN SAISHIN NO CHIRYO (Latest methods for treating dermal diseases - the Latest methods of treatment of skin diseases)", 2005-2006 (NankodoCo., Ltd.)

Non-patent document 2: "HYOJUN HIFUKAGAKU (Standard dermatology - Standard dermatology)", 7-th of the W (Igaku-Shoin Ltd.)

Objectives of the invention

Known standard tools for the prevention and/or treatment of skin damage caused by UV radiation include UV-scattering agent, which prevents the absorption of ultraviolet radiation by the skin, such as titanium oxide, UV absorbers, such as ethylhexyl-p-metaxalona acid, or an antioxidant that traps free radicals formed by ultraviolet light. UV-scattering agent or absorber of UV radiation, however, do not use every day, although it effectively prevents sunburn outdoors. Antioxidant provides some problems in terms of stability and security. In addition, some funds for treatment caused by UV radiation skin damage limited to symptomatic drugs for treatment. Thus, the need to develop a composition for reducing damage caused by ultraviolet radiation, the preparation for external use on the skin, anti-wrinkle, sunscreen, a pharmaceutical composition for treating and/or preventing skin diseases, food composition or pharmaceutical product for cataract, which can be used daily and is the tsya stable and secure.

Ways of solving the problem

The present invention provides a composition for reducing damage caused by ultraviolet radiation comprising one or more compounds selected from the group consisting of methionine and its derivatives and/or salts.

In the composition according to the invention to reduce damage caused by UV radiation, methionine, described above, may be in the D-form.

The present invention provides a composition for reducing damage caused by ultraviolet radiation comprising one or more compounds selected from the group consisting of D-serine and its derivatives and/or salts.

In the composition according to the invention to reduce damage caused by UV radiation, derived D-serine, described above, may be D-cycloserine.

The composition according to the invention to reduce damage caused by UV radiation, can be applied as a preparation for external use on the skin.

In the composition according to the invention to reduce damage caused by UV radiation, the preparation for external use on the skin, described above, can be a remedy against wrinkles.

In the composition according to the invention to reduce the damage caused by ultrafioletowymi radiation, the preparation for external use on the skin, described above, may be a sunscreen.

In the composition according to the invention to reduce damage caused by UV radiation, the preparation for external use on the skin, described above, can be used as a pharmaceutical product for skin diseases.

Skin disease, described above, may be selected from the group consisting of erythema, solar dermatitis, chronic actinic dermatopathy, actinic keratosis, actinic heylita, disease favr-Rokusho, photodermatosis, photodermatitis, breakover dermatitis, photosensitive drug rash, polymorphic light eruption, hydroa vacciniforme, light smallpox, solar urticaria, chronic photosensitive dermatitis, pigmented xeroderma, freckles, porphyria, pellagra, a disease of Hartnup, solar keratosis, dermatomyositis, flat shingles, disease Daria, red nails of pityriasis, rosacea, atopic dermatitis, chloasma, herpes simplex, lupus erythematosus, squamous cell carcinoma, basal cell carcinoma and disease Bowen.

In the composition according to the invention to reduce damage caused by UV radiation, pharmaceutical product for skin diseases, described above, may be the treatment for skin diseases.

In the composition according to the present invention to reduce damage caused by UV radiation, pharmaceutical product for skin diseases, described above, may be a means to prevent skin diseases.

The composition according to the present invention to reduce damage caused by UV radiation, can be used as food.

The composition according to the present invention to reduce damage caused by UV radiation, can be used as a pharmaceutical product for cataract.

In the composition according to the present invention to reduce damage caused by UV radiation, pharmaceutical product for cataract, described above, can be a tool for the treatment or prevention of cataracts.

The composition according to the present invention to reduce damage caused by UV radiation, can be applied as eye drops.

Cataract, described above, may be senile cataract.

The present invention provides a composition except that the composition is for oral administration to reduce damage caused by UV radiation comprising one or more compounds, the curse of the group, consisting of methionine and its derivatives and/or salts. Methionine, described above, may be in the D-form.

The present invention provides a method of treating and/or preventing skin diseases caused by exposure to ultraviolet radiation, including the stage of introduction of the composition to reduce damage caused by UV radiation, where the composition consists of one or more compounds selected from the group consisting of methionine and D-serine, as well as their derivatives and/or salts. Skin disease, described above, may be selected from the group consisting of erythema, solar dermatitis, chronic actinic dermatopathy, actinic keratosis, actinic heylita, disease favr-Rokusho, photodermatosis, photodermatitis, breakover dermatitis, photosensitive drug rash, polymorphic light eruption, light smallpox, solar urticaria, chronic photosensitive dermatitis, pigmented xeroderma, freckles, porphyria, pellagra, a disease of Hartnup, solar keratosis, dermatomyositis, flat shingles, disease Daria, red nails of pityriasis, rosacea, atopic dermatitis, chloasma, herpes simplex, lupus erythematosus, squamous cell carcinoma, basal cell carcinoma and disease Bowen. Methionine, described above, can find the camping in D-form. Derived D-serine, described above, may be D-cycloserine.

The present invention provides a method of treating and/or preventing skin diseases caused by exposure to ultraviolet radiation, including the stage of introduction of the composition to reduce damage caused by UV radiation, where the composition consists of one or more compounds selected from the group consisting of methionine and its derivatives and/or salts, with the exception of oral compositions. Skin disease, described above, may be selected from the group consisting of erythema, solar dermatitis, chronic actinic dermatopathy, actinic keratosis, actinic heylita, disease favr-Rokusho, photodermatosis, photodermatitis, breakover dermatitis, photosensitive drug rash, polymorphic light eruption, light smallpox, solar urticaria, chronic photosensitive dermatitis, pigmented xeroderma, freckles, porphyria, pellagra, a disease of Hartnup, solar keratosis, dermatomyositis, flat shingles, disease Daria, red nails of pityriasis, rosacea, atopic dermatitis, chloasma, herpes simplex, lupus erythematosus, squamous cell carcinoma, basal cell carcinoma and disease Bowen. Methionine, described above, may be in the D-form.

The present invention provides a method for improving the cosmetic condition of the skin, including the stage of introduction of the composition to reduce damage caused by UV radiation, where the composition consists of one or more compounds selected from the group consisting of methionine and D-serine, as well as their derivatives and/or salts. A method for improving the cosmetic condition of the skin described above, the composition for reducing damage caused by ultraviolet radiation comprising one or more compounds selected from the group consisting of methionine and D-serine, as well as their derivatives and/or salts described above may be a preparation for external use on the skin or food composition. Methionine, described above, may be in the D-form. Derived D-serine, described above, may be D-cycloserine.

The present invention provides a method for improving the cosmetic condition of the skin, including the stage of introduction of the composition except that the composition is for oral administration to reduce damage caused by UV radiation, where the composition consists of one or more compounds selected from the group consisting of methionine and its derivatives and/or salts. A method for improving the cosmetic condition of the skin described above, the composition is and except the composition is for oral administration to reduce damage caused by UV radiation comprising one or more compounds selected from the group consisting of methionine and its derivatives and/or salts described above may be a preparation for external use on the skin. Methionine, described above, may be in the D-form.

A method for improving the cosmetic condition of the skin according to the invention, the cosmetic improvement of the skin condition includes, among other things, the treatment against wrinkles and/or sunscreen processing.

The present invention can provide a method of treatment and/or prevention of cataracts, including the stage of introducing a composition comprising one or more compounds selected from the group consisting of methionine and D-serine, as well as their derivatives and/or salts. Methionine, described above, may be in the D-form. Derived D-serine, described above, may be D-cycloserine.

In the method of treatment and/or prevention of cataracts according to the invention a pharmaceutical product for cataract, described above, may be eye drops.

In the method of treatment and/or prevention of cataracts according to the invention cataract, described above, may be senile cataract.

Used in the present application is a salt of methionine, D-serine or D-is closerin refers to any salt, includes metal salts and salts of amines, provided that the effect of reducing damage caused by ultraviolet radiation provided by methionine, D-serine or D-cycloserine, not reduced. Salt of the metal described above, may include a salt of an alkaline metal salt, alkaline earth metal, etc., an amine Salt, described above, may include a salt of triethylamine, salt benzylamine etc.

Used in this application "derived" methionine or D-serine refers to a molecule of methionine or D-serine, which is covalently linked with any substitute group at its amino group, carboxyl group or side chain, provided that the effect of reducing damage caused by ultraviolet radiation provided by methionine or D-serine, is not reduced. Replacement group specified above, including, without limitation, the protective group, such as N-phenylacetylene group, 4,4'-dimethoxytrityl (DMT) group, and so on; a biological macromolecule such as a protein, peptide, saccharide, lipid, nucleic acid, etc.; a synthetic polymer, such as polystyrene, polyethylene, polyvinyl, complex, polyester and so on; and a functional group, such as ester group, etc., Ester group, mentioned above, may include, for example, methyl ester, ethyl ester, other aliphatic complex e is Il or aromatic ester. In the derived D-serine, as described above, the amino and/or carboxyl group adjacent to the α (alpha)-carbon atom of the amino acids, can form a heterocyclic ring, as in the case of D-cycloserine, together with any group.

Since the amino acid exists in the form of optical isomers, which is in L-form or D-form and natural protein consists of L-amino acids linked by peptide bonds and are used only L-amino acids with some exceptions, for example, a wall of bacterial cells, believed that in mammals, including humans, are present and are used only L-amino acids (Kinouchi, T. et al., TANPAKUSHITSU KAKUSAN KOSO (PROTEINS, NUCLEIC ACIDS AND ENZYMES), 50:453-460(2005), Lehninger Principles of Biochemistry [Vol 1] 2nd ed., pages 132-147 (1993), translated from the Japanese language, Hirokawa Publishing Co., Harper's Biochemistry, original version, 22nd ed., pages 21-30 (1991), translated from the Japanese language, Maruzen Co., Ltd.). Thus, for a long time as amino acids in the scientific and industrial relation was mostly used only L-amino acids.

Exceptional cases, when using D-amino acid include, for example, the case of using as a raw material for antibiotics produced by a microorganism and a case of food additives using D-amino acids in a mixture of DL-amino acids only to reduce cost by includedirective with getting only L-amino acids from a mixture of L-amino acids and D-amino acids. However, industry has not been a single case of using only the D-amino acid not containing L-amino acids, as biologically active substances.

D-serine and D-aspartic acid have been studied to a relatively high level due to its higher relations D-forms. D-serine is localized in the brain and the hippocampus, known to be involved in the modulator of the NMDA receptor in the brain. D-aspartic acid, as demonstrated localized in the testis and the pineal body, and, as reported, is involved in the regulation of hormone secretion (Unaccepted application for patent of Japan 2005-3558). However, the physiological effects of D-serine and D-aspartic acid on the skin have not been studied.

As indicated in the Examples described below, until now it was not known that methionine, D-serine and D-cycloserine as having L-form or D-form, or a mixture, caused the effect of reducing damage caused by ultraviolet radiation. Thus, the composition according to the present invention to reduce damage caused by UV radiation, including methionine, D-serine and/or D-cycloserine is a new invention.

Recently reported that ddY mice were given access to 10 mm aqueous solution of D-amino acids for 2 weeks, and then in each organ was determined by the concentration of D-is minamikata, which was 3-1000 pmol each gland the pineal gland and 2-500 pmol per gram of wet brain tissue (Morikawa, A. et al., Amino Acids, 32:13-20 (2007)). On the basis of this message were calculated lower limit of the daily dose of methionine, D-serine and D-cycloserine contained in the composition of the present invention.

As indicated in the Examples described below, methionine, which relates to the present invention exhibits the effect of reducing damage caused by ultraviolet radiation, at a concentration ranging from 0.001 to 100 μm (micromoles) in the culture of human fibroblasts. Accordingly, the number of methionine contained in the pharmaceutical compositions of the present invention, the tool against wrinkles, sun means the preparation for external use on the skin and pharmaceutical product for cataract may vary within wide limits, provided that the methionine is delivered to the skin fibroblast tissuein vivoin the concentration range indicated above. In that case, when the composition of the present invention is the preparation for external use, the content of methionine can be from 0,0000015 mass% to 50 mass% in the total amount of the composition of the invention or to the maximum mass concentration, which may be introduced into the composition. Thus, if the composition described above, it is the preparation for external use, the content of methionine is preferably from 0.000003% by weight to 30% by weight, most preferably from 0.00003% by weight to 3% by weight. The lower limit of the daily dose of D-methionine contained in the composition of the present invention, may be of 0.01 ng, preferably 0.1 ng, more preferably 1 ng per kg of body weight. The lower limit of the daily dose of L-methionine contained in the composition of the present invention, less than the clinical dose of the drug (2 mg or more per kg of body weight), and may be 0.01 mg, preferably 0.1 mg, more preferably 1 mg per kg of body weight.

As indicated in the Examples described below, D-serine invention exhibits the effect of reducing damage caused by ultraviolet radiation, at a concentration ranging from 0.01 to 100 μm on the culture of human fibroblasts. Thus, the number of D-serine contained in the pharmaceutical compositions of the present invention, the tool against wrinkles, sun means the preparation for external use on the skin and pharmaceutical product for cataract may vary within wide limits, provided that D-serine is delivered to the skin fibroblast tissuein vivoin the concentration range indicated above. In that case, when the composition of the present invention is the preparation for external use, you provide the e D-serine can be from 0,000015 mass% to 50 mass% in the total amount of the composition of the invention or to the maximum mass concentration, that it is possible to introduce into the composition. Thus, if the composition described above, is a drug for external use, the content of D-serine is preferably from 0.00003% by weight to 30% by weight, most preferably from 0.0003% by weight to 3% by weight. If the composition of the present invention is a medicine for internal use, the content of D-serine may range from 0.00001% by mass to 100% by weight. If the composition of the invention is the preparation for internal use, the content of D-serine is preferably from 0.00002% by weight to 80% by weight, most preferably from 0.0002 mass% to 60 mass%. The lower limit of the daily dose of D-serine contained in the composition of the present invention, may be of 0.01 ng, preferably 0.1 ng, more preferably 1 ng per kg of body weight.

As indicated in the Examples described below, D-cycloserine invention exhibits the effect of reducing damage caused by ultraviolet radiation, at a concentration in the range from 1 to 100 microns (micromoles) in the culture of human fibroblasts. Thus, the number of D-cycloserine contained in the pharmaceutical compositions of the present invention, the tool against wrinkles, sun means the preparation for external use on the skin and pharmaceutical product for cataract, can the be changed within wide limits, provided that D-cycloserine delivered in the fibroblast in the skin tissuein vivoin the concentration range indicated above. If the composition of the present invention is the preparation for external use, the content of D-cycloserine may be from 0,0000015 mass% to 50 mass% in the total amount of the composition of the invention or to the maximum mass concentration, which may be introduced into the composition. Thus, if the composition described above, is a drug for external use, the content of D-cycloserine is preferably from 0.000003% by weight to 30% by weight, most preferably from 0.00003% by weight to 3% by weight. The lower limit of the daily dose of D-cycloserine contained in the composition of the present invention, may be of 0.01 μg (micrograms), preferably 0.1 tomcg (micrograms), more preferably 1 μg (micrograms) per kg of body weight.

The pharmaceutical composition of the present invention may optionally include one or more pharmaceutically acceptable additives, in addition to methionine and D-serine, salts and/or derived D-serine and methionine, is capable of releasing methionine and D-serine by the action of enzymes metabolizing the drug, etc.,in vivoprovided that the effect of reducing damage caused by ultraviolet radiation, about speciaaly methionine and D-serine, not reduced. Such an additive includes, among other things, a diluent, a substance that promotes inflammation, binder, adhesive, moving substance, a substance that promotes fluidity, plasticizer, baking powder, solvent-carrier, a buffering agent, colorant, flavor, sweetener, preservative, stabilizer, adsorbent, as well as other pharmaceutical additives known qualified personnel.

The remedy for wrinkles and/or sunscreen of the present invention can be prepared using only the methionine, D-serine and D-cycloserine, salts of methionine, D-serine and D-cycloserine and/or derivatives capable of releasing methionine, D-serine and D-cycloserine under the action of enzymes metabolizing the drug, etc.,in vivo. However, other components used in preparations for external use on the skin, such as cosmetic and pharmaceutical products, including medical cosmetics, can be properly included in the composition so that was not reduced by the effect of the invention. Such other components (not necessarily enter into the composition components include, for example, oils, surfactants, detergents, dyes, water, alcohols, thickeners, chelating agents, silicones, antioxidants, UV absorbers, smash the living substance, flavors, various medicinal components, preservatives, pH regulators, a neutralizing substance, etc.

The preparation for external use on skin according to the present invention can be any of the tools traditionally used as a drug for external use on the skin and cosmetic compositions, such as ointment, cream, emulsion, lotion, facial mask, bath salt, etc., and their dosage forms not specified.

In preparations for external use on skin according to the invention may be properly optionally includes other components used in preparations for external use on the skin, such as cosmetic and pharmaceutical products, including medicinal cosmetics, provided that the effect of reducing damage caused by ultraviolet radiation provided by methionine, D-serine and D-cycloserine, not reduced. Such other components (not necessarily enter into the composition components include, for example, oils, surfactants, detergents, dyes, water, alcohols, thickeners, chelating agents, silicones, antioxidants, UV absorbers, wetting agents, flavoring agents, various medicinal components, preservatives, pH regulators, a neutralizing substance.

Food composition is altoadige of the invention may also include, in addition to D-serine and D-cycloserine, salts of D-serine and D-cycloserine and/or derivatives capable of releasing D-serine and D-cycloserine under the action of enzymes metabolizing the drug, etc.,in vivoand additionally permitted in the food industry component, such as a spice, dye, preservative, provided that the effect of reducing damage caused by ultraviolet radiation provided by D-serine and D-cycloserine, not reduced.

Food composition of the present invention can be any of the traditionally used as a food composition, such as a drink, chewing marmalade, candy, sweetener tablets, which it is not limited.

Brief description of figures

Figure 1 is a graph showing the effect of adding L - or D-methionine before treatment of normal fibroblasts of human skin to ultraviolet radiation.

Figure 2 is a graph showing the effect of adding D-methionine before treatment of normal fibroblasts of human skin to ultraviolet radiation.

Figure 3 is a graph showing the effect of adding D-methionine after treatment of normal fibroblasts of human skin to ultraviolet radiation.

Figure 4 is a graph, a description of the m shows the effect of adding L - or D-serine before treatment of normal fibroblasts of human skin to ultraviolet radiation.

Figure 5 is a graph showing the effect of adding D-serine before treatment of normal fibroblasts of human skin to ultraviolet radiation.

Figure 6 is a graph showing the effect of adding D-serine after treatment of normal fibroblasts of human skin to ultraviolet radiation.

Figure 7 is a graph showing the effect of adding D-cycloserine after treatment of normal fibroblasts of human skin to ultraviolet radiation.

Description of embodiments

Examples of the present invention, described below, are intended only to illustrate the invention and are not limiting its scope. Scope of the invention be limited only in accordance with the contents of the formula.

All documents cited in the present description, are fully incorporated by reference.

Example 1

The effect of reducing damage caused by ultraviolet radiation, under the action of methionine

Methods

Cell culture

Used by the cell was a commercial neonatal fibroblast human skin (Cryo NHDF-neo, Sanko-Junyaku Co., Ltd.). The indicated cell type was inoculable 2×105cells/ml in commercial culture plate with a diameter of 35 mm (BD FALCON 353001, Becton Dickinson Japan), where they were cultured in to marcheschi environment for cell culture (D-MEM (1 g/l glucose, Wako Pure Chemical Industries, Ltd.) with the addition of 10% fetal bovine serum (hereafter referred to as "normal medium"). The cell described above can be cultured in normal medium, described above, with the addition of antibiotic (15240-062, Gibco) at a concentration of 1%. The specified cell were cultured for approximately 24 hours under 5%CO2in a saturated water vapor atmosphere at 37°C (degrees Celsius).

Then the culture medium for culturing cells, described above, was replaced by 1 ml of medium BSO with the addition of an inhibitor of glutathione biosynthesis BSO (L-buthionine-(S,R)-sulfoximine, Wako Pure Chemical Industries, Ltd.) when 1×10-3% where the culture was maintained for approximately 24 hours under 5%CO2in a saturated water vapor atmosphere at 37°C (degrees Celsius). Wednesday BSO, described above, were prepared by 200-fold dilution of stock solution containing 0.2% alcohol solution BSO, the normal environment described above.

Adding amino acids before treatment with ultraviolet radiation

To determine the effect of adding methionine before treatment with ultraviolet radiation (hereinafter called "the addition of methionine to the radiation") culture medium was changed on Wednesday BSO with the addition of 0.0001 - 100 μm (micromoles) L-methionine (131-01603, Wako Pure Chemical Industries Ltd.) or D-methionine (2807, Peptide Institute Inc.) 24 hours is about exposure. The irradiation with ultraviolet light after replacing the medium with addition of 0.1 ám (micromoles) D-Proline (165-14671, Wako Pure Chemical Industries Ltd.) used as a positive control, whereas irradiation with ultraviolet light environment without the addition of this amino acid was used as negative control.

Environment for UV irradiation

Chloride iron (II) was dissolved in distilled water at 2×10-3% and the resulting solution was subjected to 200-fold dilution (final concentration: 1×10-5%) phosphate-saline buffer PBS ( + ) containing calcium ion and magnesium ion, receiving environment (hereinafter called the "Environment for UV irradiation"), which was pre-heated to 37°C before use.

UV irradiation

Before UV-A exposure, culture medium was replaced by 1 ml of medium for UV irradiation, as described above. UV-A irradiation was performed using a device uniform UV irradiation UVE-502S+EL-160 (SAN-EI ELECTRIC), irradiating the culture plate with a height of approximately 20 cm UV radiation with a wavelength of 320 to 400 nm at 8 j/cm2and 9 j/cm2in a state where the cover is appropriate culture plate was removed. The dose of UV radiation was measured using a UV radiometer UVR-3036/S (Topcon Corporation).

Adding amino acids after treatment with ultraviolet radiation

After UV-A irradiation at 8 j/cm2Wednesday is amanali normal environment, described above, and maintained in culture at 5% CO2in a saturated water vapor atmosphere at 37°C (degrees Celsius) for 40 hours. To determine the effect of adding methionine after UV-irradiation (hereinafter called "adding methionine after exposure") in the specified environment after 40 h of cultivation was added to 0.001-100 μm (micromoles) L - or D-methionine. The irradiation with ultraviolet light after replacing the medium with addition of 0.1 ám (micromoles) D-Proline was used as a positive control, whereas irradiation with ultraviolet light environment without the addition of this amino acid was used as negative control.

Assessment of cell damage under irradiation before and after adding

The next step in the cultural medium was added Alamar Blue (trade name, Biosource, Biosource International Inc. and Invitrogen) to a final concentration of 10%, and then determined the fluorescence intensity of the supernatant after three hours at the wavelength of excitation 544 nm and the wavelength of fluorescence 590 nm, as described by Ahmed S. A. et al. J. Immunol. Method. 170, 211-224 (1994), and in accordance with the manufacturer's instructions. The percentage of viable cells was obtained as a percentage, the ratio, calculated by dividing the fluorescence intensity of Alamar Blue when each condition of the experiment, the fluorescence intensity of the negative control group without to is where it is refuelled amino acids.

The effect of adding methionine before irradiation (1)

The Figure 1 shows the results of the experiment on the effect of L - or D-methionine on the damaged fibroblasts induced by treatment with ultraviolet radiation UV-A at 9 j/cm2. Error bars for relevant experimental conditions correspond to the standard deviations of the measured values of the results of the experiments repeated four times under the same conditions. The asterisk (*) indicates P<5%, ( * * ) denotes P<1% ( * * * ) denotes P<0,1% according to the criterion of Bonferroni/Dunn.

The percentage of viable cells without the addition of amino acids before the irradiation of UV-A to 9 j/cm2(negative control) was 24%. The percentage of viable cells with the addition of D-Proline at 0.1 μm (micromoles) before irradiation (positive control) was 100%, which indicates that the suppression of cell death. Add before irradiation of D-methionine at 0.01 µm (micromoles), 0.1 ám (micromoles), 1 μm (micromoles), 10 μm (micromoles) or 100 μm (micromoles) resulted in the percentage of viable cells 102%, 81%, 97%, 114% or 76%, respectively. Add before irradiation of L-methionine in 0,001 µm (micromoles), 0.01 µm (micromoles), 0.1 ám (micromoles), 1 μm (micromoles), 10 μm (micromoles) or 100 μm (micromoles) resulted in the percentage of viable cells 40%, 72%, 67%, 45%, 73% and the and 62%. Based on the presented results it can be argued that the addition of L - or D-methionine resulted in increase in the percentage of viable cells and reduced cell death.

The effect of adding methionine before irradiation (2)

The Figure 2 shows the results of the experiment on the effect of D-methionine on the damaged fibroblasts induced by treatment with ultraviolet radiation UV-A at 9 j/cm2. Error bars for relevant experimental conditions correspond to the standard deviations of the measured values of the results of the experiments repeated three or four times under the same conditions. The asterisk (*) indicates p<5% according to the criterion of Bonferroni/Dunn.

The percentage of viable cells without UV irradiation and without the addition of amino acids (hereinafter called "without UV-irradiation") was 100%. The percentage of viable cells without the addition of amino acids before the irradiation of UV-A to 9 j/cm2(negative control) was 69%. The percentage of viable cells with the addition of D-Proline at 0.1 μm before irradiation (positive control) was 88%, which indicates a decrease in cell death. Add before irradiation of D-methionine in 0,0001 μm (micromoles) and 0.1 μm (micromoles) resulted in the percentage of viable cells to 50% and 101%. Based on the presented results it can be argued that the addition of D-methionine in 0,0001 μm (micromoles) did not lead to any increase in the percentage of viable cells, however, the addition of D-methionine at 0.1 μm (micromoles) have led to the increase in the percentage of viable cells and reduced cell death.

The effect of adding methionine after irradiation

The Figure 3 shows the results of the experiment on the effect of D-methionine on the damaged fibroblasts induced by treatment with ultraviolet radiation UV-A at 8 j/cm2. Error bars for relevant experimental conditions correspond to the standard deviations of the measured values of the results of the experiments repeated four times under the same conditions. The asterisk (***) denotes p <0,1% according to the criterion of Bonferroni/Dunn.

The percentage of viable cells without the addition of amino acids after exposure to UV-A 8 j/cm2(negative control) was 64%. The percentage of viable cells in the presence of D-Proline added at 0.1 μm (micromoles) after irradiation, was 82%, which indicates a decrease in cell death. Add after irradiation of D-methionine in 0,01μm (micromoles), 0.1 ám (micromoles), 1 μm (micromoles), 10μm (micromoles) or 100 μm (micromoles) resulted in the percentage of viable cells 93%, 84%, 82%, 81% approximately 87%. Based on the presented results it can be argued that the addition of D-methionine resulted in increase in the percentage of viable cells and reduce Vibelicious. It was also shown that the effect of reducing cell death was observed regardless of the time Appendix D-methionine before or after UV irradiation. In addition, L-methionine also reduced cell death caused by UV-radiation. Thus, suggested that there is no relation to the time of addition of L-methionine, added before or after UV exposure.

Example 2

The effect of reducing damage caused by ultraviolet radiation, under the action of serine

Methods

The cultivation of cells, the addition of amino acids before UV-irradiation, UV-irradiation, the addition of amino acids after UV-irradiation and measurement of cell damage was carried out similarly to Example 1. Treatment with ultraviolet radiation (UV-A) was carried out at a 7.5 or 9 j/cm2. To determine the effect of adding serine before irradiation with ultraviolet light (hereinafter called "add serine before irradiation) and the effect of adding serine after irradiation with ultraviolet light (hereinafter called "add serine after irradiation") used L-serine (197-00403, Wako Pure Chemical Industries Ltd.) and D-serine (197-08823, Wako Pure Chemical Industries Ltd.) when 0,0001 - 100 μm (micromoles). The effect of adding serine after irradiation were evaluated under irradiation of cells with the energy density of 7.5 j/cm2UV-A, followed by the replacement of environment normal environment in which the crop is maintained for 21 hours and the addition of D-serine to the environment, cultivated for 21 hours.

The results add serine before irradiation (1)

The Figure 4 shows the results of the experiment on the effect of adding L-serine and D-serine before irradiation damage fibroblasts caused by irradiation of UV-A at 9 j/cm2. Error bars for relevant experimental conditions correspond to the standard deviations of the measured values of the results of the experiments repeated four to six times under the same conditions. The asterisk (*) indicates p<5% according to the criterion of Bonferroni/Dunn.

The intensity of fluorescence of Alamar Blue (trade name) without ultraviolet irradiation was 794. The fluorescence intensity without adding amino acids before the irradiation of UV-A at 9 j/cm2(negative control) was 140. The intensity of fluorescence with the addition of D-Proline at 0.1 μm (micromoles) before irradiation (positive control) amounted to 610, indicating a reduced cell damage. Fluorescence intensity with the addition of D-serine at 0.01 µm (micromoles), 0.1 ám (micromoles), 1 μm (micromoles) and 10 μm (micromoles) before irradiation was 445, 402, 371 and 491, respectively. Fluorescence intensity with the addition of L-serine at 0.1 μm (micromoles), 1 μm (micromoles) and 10 μm (micromoles) per the d exposure was $ 265, 227 and 270, respectively. Based on the presented results it can be argued that the addition of L-serine to radiation almost did not lead to any decrease in cell damage. Meanwhile, the addition of D-serine before irradiation resulted in statistically significant increases in fluorescence intensity, which indicates a decrease in cell damage.

The results add serine before irradiation (2)

The Figure 5 shows the results of the experiment on the effect of adding D-serine before irradiation damage fibroblasts caused by irradiation of UV-A at 8 j/cm2. Error bars for relevant experimental conditions correspond to the standard deviations of the measured values of the results of the experiments repeated four times under the same conditions. The asterisk (*) indicates p<5% according to the criterion of Bonferroni/Dunn.

The percentage of viable cells without ultraviolet irradiation was 100%. The percentage of viable cells without the addition of amino acids before irradiation with UV-A 8 j/cm2(negative control) was 77%. The percent of viable cells with the addition of D-serine at 0,0001 μm (micromoles), 0.01 µm (micromoles) and 10 μm (micromoles) before irradiation was 74%, 92% and 93%, respectively. Based on the presented results it can be argued, chopourian cells, caused by ultraviolet radiation, characterized by the fact that the addition of D-serine at 0,0001 μm (micromoles) have led to the increase in the percentage of viable cells, the addition of D-serine at 0.1 μm (micromoles) and 10 μm (micromoles) have led to the increase in the percentage of viable cells, indicating a reduction in cell death.

The results add serine after irradiation

The Figure 6 shows the results of the experiment on the effect of adding D-serine after exposure to injury fibroblasts caused by irradiation of UV-A at 7.5 j/cm2. Error bars for relevant experimental conditions correspond to the standard deviations of the measured values of the results of the experiments, repeated eight times under the same conditions. The asterisk (*) indicates p<5% according to the criterion of Bonferroni/Dunn.

The intensity of fluorescence of Alamar Blue (trade name) without ultraviolet irradiation was 764. The fluorescence intensity without adding amino acids after exposure to UV-A at 7.5 j/cm2(negative control) was 348. The intensity of fluorescence with the addition of D-Proline at 0.1 μm (micromoles) after irradiation (positive control) amounted to 579, indicating a decrease in cell damage. Fluorescence intensity with the addition of D-serine at the 0.01 MK is (micromoles), 0.1 ám (micromoles), 1 μm (micromoles), 10 μm (micromoles) and 100 μm (micromoles) after irradiation was 697, 735, 742, 664 and 663, respectively. Based on the presented results it can be argued that the addition of D-serine after irradiation resulted in a statistically significant increase in fluorescence intensity, which indicates a decrease in cell damage. It was also shown that the effect of reducing cell damage was achieved regardless of the time of adding D-serine produced before or after UV exposure.

Example 3

The effect of reducing damage caused by ultraviolet radiation, the effects of D-cycloserine

Methods

The cultivation of cells, the addition of amino acids before UV-irradiation, UV-irradiation, the addition of amino acids after UV-irradiation and measurement of cell damage was carried out similarly to Example 1. Treatment with ultraviolet radiation (UV-A) was carried out at 9 j/cm2. To determine the effect of adding D-cycloserine before irradiation with ultraviolet light (hereinafter called "add cycloserine before irradiation") used D-cycloserine (C6880, Sigma) at of 0.0001-100 microns.

The effect of adding D-cycloserine before irradiation

The Figure 7 shows the results of the experiment on the effect of adding D-cycloserine before irradiation damage is giving fibroblasts, caused by UV-A irradiation at 9 j/cm2. Error bars for relevant experimental conditions correspond to the standard deviations of the measured values of the results of the experiments repeated three or four times under the same conditions. The symbol (+) and asterisk (***) indicate p<10% and p<0.1 percent, respectively, according to the criterion of Bonferroni/Dunn.

The percentage of viable cells without the addition of amino acids before UV-A irradiation at 9 j/cm2(negative control) was 53%. The percentage of viable cells with added D-cycloserine at 0.1 nm, 10 nm, 100 nm, 1 μm (micromoles), 10 μm (micromoles) and 100 μm (micromoles) before irradiation was 60%, 60%, 63%, 74%, 69% and 109%. Based on the presented results it can be argued that the addition of D-cycloserine has led to an increase in the percentage of viable cells, indicating a reduction in cell death.

On the basis of the present invention, the following are the formulations of examples of compositions, including methionine, serine and/or D-cycloserine, such as emulsion composition, the composition of the patch, tablet, soft capsule, granule, drink, candy, cookies, pasta, miso, French dressing, mayonnaise, French bread, soy sauce, yogurt, dried seasoning powder for rice dressing/sauce, natto (Japanese fermented soybean paste), natto, unrefined black vinegar, BAP is, body cream, gel composition, otshelushevaya mask, wet wrap, emulsion, lotion for the face and aerosol composition. Methionine in the following examples, the compositions were in the D-form or L-form. These examples of compositions are given solely for the purpose of example and are not considered as limiting the scope of the invention.

Example compositions 1 (emulsion composition)
(Composition)Table of contents
(mass%)
Methionine, D-serine and/or D-cycloserine0,42
Beganovic alcohol0,2
Cetanol0,5
Glycerin monoether fatty acids1,8
Hydrogenated castor oil POE (60)1,0
White petrolatum2,0
Liquid paraffin10,0
Isopropylmyristate3,0

Methylpolysiloxanes (6cs)1,5
Conc. glycerin13,0
Dipropyleneglycol2,0
Carboxyvinyl polymer0,25
Sodium hyaluronate0,005
The potassium hydroxideif necessary
Lactic acidif necessary
Sodium edetateif necessary
Ethylparabenif necessary
Purified waterup to 100%
100,00

Example composition 2 (Composition of the patch)
(Composition)Table of contents
(mass%)
Methionine, D-serine and/or D-cycloserine0,3
Polyacrylic acid3,0
Polyacrylate sodium2,5
Gelatin0,5
Sodium carboxymethylcellulose4,0
Polyvinyl alcohol:0,3
Conc. glycerin14,0
1,3-Butyleneglycolto 12.0
Aluminum hydroxide0,1
Sodium edetate0,03
Methylparaben0,1
Purified waterup to 100%
100,00
Example of composition 3 (Pill)
(Composition)Content (mg/tablet)

D-serine and/or D-cycloserine360,5
Lactose102,4
Calcium carboxymethylcellulose29,9
Hydroxypropylcellulose6,8
Magnesium stearate5,2
Crystalline cellulose10,2
515,0

Example of composition 4 (Pill)
(Composition)Content (mg/tablet)
Ester of sucrose70
Crystalline cellulose74
The methylcellulose36
Glycerin25
D-serine and/or D-cycloserine475
N-Acetylglucosamine200
150
Vitamin E30
Vitamin B620
α(alpha)-Lipoic acid20
Coenzyme Q1040
Ceramide (extract konnyaku)50
L-Proline300
1500

Example of composition 5 (Soft capsule)
(Composition)Content (mg/capsule)

Food soybean oil530
Extract ofEucommia ulmoides50
Ginseng extract50
D-serine and/or D-cycloserine100
Royal jelly50
30
GABA30
Beeswax60
Gelatin375
Glycerin120
Glycerol ester of fatty acids105
1500

1500
An example of the composition 6 (Soft capsule)
(Composition)Content (mg/capsule)
Germ oil brown rice659
D-serine and/or D-cycloserine500
Resveratrol1
The germ extract Lotus100
Elastin180
DNA30
Folic acid30

Example compositions 7 (Pellet)
(Composition)Content (mg/pack)
D-serine and/or D-cycloserine400

Vitamin C100
Soybean isoflavone250
Restored lactose300
Soy oligosaccharide36
Aritra36
Dextrin30
Flavor24
Citric acid24
1200

An example of the composition 8 (Drink)
(Composition)Content (g/60 ml)
Extract ofEucomma ulmoides 1,6
Ginseng extract1,6
D-serine and/or D-cycloserine1,6
Restored maltose syrup28
Aritra8
Citric acid2
Flavor1,3
N-Acetylglucosamine1
Sodium hyaluronate0,5
Vitamin E0,3
Vitamin B60,2
Vitamin B20,1
α(alpha)-Lipoic acid0,2
Coenzyme Q101,2
Ceramide (extract konnyaku)0,4

L-Proline2
Purified the ode to 60 ml
60

Example compositions 9 (candy)
(Composition)The content (mass%)
Sugar50
Syrup48
D-serine and/or D-cycloserine1
Flavor1
100

An example of the composition 10 (Biscuits)
(Composition)The content (mass%)
Wheat flour soft varieties45,0
Oilof 17.5
Sugar20,0
D-serine and/or D-cycloserine4,0
Egg12,5
Flavor1,0
100

The method of preparation of Example composition 10 (Biscuits)

Sugar add portions to the oil while stirring, then add the egg, D-serine and/or D-cycloserine together with flavoring and mix. After complete mixing uniformly add the sifted flour and slowly stir, then put the dough in the refrigerated Cabinet for ottoni. Then the dough is shaped and baked for 15 minutes at 170°C (degrees Celsius) with biscuits.

An example of the composition 11 (Paste miso (soy))
(Composition)Content (g)
Soy1000
Orogeny rice1000
Sol420
D-serine and/or D-cycloserine158
Waterbalance
4000

The method of preparation of Example composition 11 (paste Miso (soy is I))

Orogeny rice thoroughly mixed with the salt. Washed soybeans soaked in three volumes of water, which then drain and add a new portion of water during boiling, which is drained through a sieve to collect the broth (liquid Takemitsu), in which dissolve D-serine and/or D-cycloserine to 10% of/about. Boiled beans immediately crushed, combined with orogeny rice, mixed with salt, to which liquid is added Takemitsu described above, containing dissolved D-serine and/or D-cycloserine, and uniformly mixed to obtain the mass of clay-like consistency. Make balls that are firmly placed in the container, leaving no voids, after which the surface content level and cover with plastic wrap. After three months, the contents transferred to a new container, level surface and cover with plastic wrap. Instead of adding D-serine and/or D-cycloserine to liquid tanimizu you can use orogeny rice, giving a large number of D-serine and/or D-cycloserine. This orogeny rice can be selected when determining the number of D-serine and/or D-cycloserine using the method described in unaccepted application for patent of Japan 2008-185558. In alternative D-serine and/or D-cycloserine, or salt can be added to commercial miso paste.

An example of the composition 12 (French dressing)
(Composition)Content (g)
Vegetable oil27,0
Vinegar30,0
Sodium chloride0,9
D-serine and/or D-cycloserine1,1
Pepper1,0
60,0

The method of preparation of Example composition 12 (French dressing)

Vinegar is combined with sodium chloride and D-serine and/or D-cycloserine, mix thoroughly, and then add the pepper.

An example of the composition 13 (Mayonnaise)
(Composition)Content (g)
Vegetable oil134,0
Vinegar5
Sodium chloride0,9
D-serine and/or D-cycloserine1
Egg yolk18

Sugar0,2
Pepper0,9
160,0

The method of preparation of Example composition 13 (Mayonnaise)

Egg yolk (room temperature) combined with vinegar, salt, pepper, and D-serine and/or D-cycloserine and mix thoroughly using a controlling device. Stirring is continued and the portions add vegetable oil to obtain the emulsion. Finally add the sugar and stir the mixture.

td align="justify"> Dry yeast
An example of the composition 14 (French bread)
(Composition)Content (g)
Flour durum wheat140
Flour soft wheat60
Sodium chloride3
Sugar6
D-serine and/or D-cycloserine1
4
Warm water128
343

The method of preparation of Example composition 14 (French bread)

The warm water combined with 1 g of sugar and dry yeast, which then leave for pre-fermentation. Flour durum wheat flour soft wheat, salt and 5 g of sugar is placed in the bowl together with D-serine and/or D-cycloserine, then add the risen yeast. After thorough mixing the dough, form into a ball and hold primary fermentation at 30°C. the Dough again, mix and leave for proofing, and then give the desired shape and subjected to final fermentation using electronic fermentation machine. After forming rolls are baking for 30 minutes in an oven at 220°C (degrees Celsius).

An example of the composition 15 (Soy sauce)
(Composition)Content (g)
Commercial soy sauce900
D-serine and/or D-cycloserine100
1000

The method of preparation of Example composition 15 (Soy sauce)

In commercial soy sauce add D-serine and/or D-cycloserine and mix thoroughly. Instead of adding D-serine and/or D-cycloserine, or their salts when fermenting soy sauce can be used orogeny rice, giving a large number of D-serine and/or D-cycloserine. This orogeny rice can be selected using quantitative analysis of D-serine and/or D-cycloserine in the manner described in unaccepted application for patent of Japan 2008-185558.

An example of the composition 16 (Yogurt)
(Composition)Content (g)
Milk880
L. bulgaricus50
S. thermophilus50
D-serine and/or D-cycloserine20
1000

The method of preparation of Example composition 16 (Yogurt)

The fermentation is carried out at a temperature of 40°C (degrees Celsius) to 45°C (degrees Celsius). Can use the camping other commercial culture of microorganisms for fermentation, and D-serine and/or D-cycloserine may be added in commercial yogurt. Instead of adding D-serine and/or D-cycloserine, or their salts, for fermentation can be used by the body, producing a large number of D-serine and/or D-cycloserine. This organism can be selected using quantitative analysis of D-serine and/or D-cycloserine in the manner described in unaccepted application for patent of Japan 2008-185558.

An example of the composition of 17 (Dried seasoning powder to rice)
(Composition)Content (g)
D-serine and/or D-cycloserine50
Red algae15
L-MSG10
Sodium chloride2
Toasted sesame seeds10
Dried flakes mackerel10

Sugar1
Soy sauce
100

An example of the composition 18 (Condiment, sauce, Natto)
(Composition)Content (g)
Commercial sauce, natto9
D-serine and/or D-cycloserine1
10

Example composition 19 (Natto)
(Composition)Content (g)
Commercial nattoto 19.9
D-serine and/or D-cycloserine0,1
20

The method of preparation of Example composition 19 (Natto)

Instead of adding D-serine and/or D-cycloserine, or their salts for the preparation of natto can be used by the body, producing a large number of D-serine and/or D-cycloserine. This organism can be selected using quantitative analysis of D-serine and/or D-is closerin way described in unaccepted application for patent of Japan 2008-185558.

An example of the composition 20 (Unrefined black vinegar)
(Composition)Content (g)
Commercial unrefined black vinegar900
D-serine and/or D-cycloserine100
1000

The method of preparation of Example composition 20 (Unrefined black vinegar)

Instead of adding D-serine and/or D-cycloserine, or their salts for the preparation of vinegar, black vinegar or raw vinegar can be used in the body, producing a large number of D-serine and/or D-cycloserine. This organism can be selected using quantitative analysis of D-serine and/or D-cycloserine in the manner described in unaccepted application for patent of Japan 2008-185558.

Example composition 21 (Cream)
(Composition)Content (%)
Liquid paraffin3
Vaseline1
Dimethylpolysiloxane1
Stearyl alcohol1,8
Beganovic alcohol1,6
Glycerin8
Dipropyleneglycol5
Oil macadamia nut2
Hydrogenated oil3
Squalane6
Stearic acid2
Cholesterolcholesterol0,5
Cetyl-2-ethylhexanoate4
Polyoxyethylene hydrogenated castor oil0,5
Self emulsifiable glycerylmonostearate3
The potassium hydroxide0,15

0,05
Trimethylglycine2
Potassium salt of diapir phosphoric acid, L-ascorbic acid, dl-alpha-tocopherol1
Tocopherol acetate0,1
Methionine, D-serine and/or D-cycloserine4
ParabenIf necessary
Trinacria edetate0,05
4-t-Butyl-4'-methoxybenzanilide0,05
Glycerylphosphorylcholine-mono-2-ethylhexanoate0,05
DyeIf necessary
Carboxyvinyl polymer0,05
Purified waterup to 100%
100

An example of the composition 22 (body cream)
(Composition)Table of contents
(mass%)
Dimethylpolysiloxane3
Decamethylcyclopentasiloxane13
Dodecamethylcyclohexasiloxane12
A copolymer of polyoxyethylene-methylpolysiloxanes1
Ethanol2
Isopropanol1
Glycerin3
Dipropyleneglycol5

/tr>
Polyethylene glycol 60005
The sodium hexametaphosphate0,05
Tocopherol acetate0,1
D-serine and/or D-cycloserine5
Extract of fennel0,1
Witch hazel extract0,1
Ginseng extract0,1
L-mentholIf necessary
p-oxybenzoicIf necessary
Trisodium edetate0,05
Disorganization0,01
Methyl bis(trimethylsiloxy)similiter - trimethoxycinnamic0,1
Yellow iron oxideIf necessary
The cobalt titanateIf necessary
Dimethyldodecylamine getalit1,5
Polyvinyl alcohol:0,1
Hydroxyethylcellulose0,1
Trimethylsiloxypenylazo acid2
PerfumeIf necessary
Purified waterUp to 100%
100

An example of the composition 23 (body cream)
(Composition)Table of contents
(mass%)
Dimethylpolysiloxane3

Decamethylcyclopentasiloxane13
Dodecamethylcyclohexasiloxane12
A copolymer of polyoxyethylene-methylpolysiloxanes1
Ethanol2
Isopropanol1
Glycerin3
Dipropyleneglycol5
Polyethylene glycol 60005
The sodium hexametaphosphate0,05
Tocopherol acetate0,1
Methionine3
The extract is of Angela 0,1
Witch hazel extract0,1
Ginseng extract0,1
L-mentholIf necessary
p-oxybenzoicIf necessary
Trisodium edetate0,05
Disorganization0,01
Isopentyl-trimethoxycinnamic-trisiloxane0,1
Yellow iron oxideIf necessary
The cobalt titanateIf necessary
Dimethyldodecylamine getalit1,5
Polyvinyl alcohol:0,1
Hydroxyethylcellulose0,1
Trimethylsulfoxonium2
PerfumeIf necessary

Purified waterUp to 100%
100

An example of the composition 24 (formulation Gel)
(Composition)Table of contents
(mass%)
Dimethylpolysiloxane5
Glycerin2
1,3-butyleneglycol5
Polyethylene glycol 15003
The polyethylene glycol 200003
Tetrachromat3
Citric acid0,01
Sodium citrate0,1
The sodium hexametaphosphate0,1
The glycyrrhizinate of dItalia0,1
Methionine, D-serine and/or D-cycloserine2
Toko is erola acetate 0,1
The root extract of Scutellaria0,1
Extract of saxifrage0,1
Trisodium edetate0,1
Xanthan gum0,3
Acrylic/C10-30 alkylacrylate crosspolymer0,05
(Pemulen TR-2)
Agar powder1,5
PhenoxyethanolIf necessary
DibutylaminoethanolIf necessary

Purified waterUp to 100%
100,00

An example of the composition 25 (Otshelushevaya mask)
(Composition)Table of contents
(mass%)
Ethanol1
1,3-Butyleneglycol6
Polyethylene glycol 40002
Olive oil1
Oil macadamia nut1
Finasteridefinasteride acid0,05
Lactic acid0,05
Sodium lactate0,1
L-ascorbate sulfate disodium0,1
Potassium salt of diapir phosphoric acid, L-ascorbic acid, dl-alpha-tocopherol0,1
D-serine and/or D-cycloserine10
Fish collagen0,1
Chondroitin sulfate sodium0,1
Sodium carboxymethylcellulose0,2
Polyvinyl alcohol:12
p-oxybenzoic If necessary
PerfumeIf necessary
Purified waterUp to 100%
100,00

An example of the composition 26 (Otshelushevaya mask)

(Composition)Table of contents
(mass%)
Ethanol10
1,3-Butyleneglycol6
Polyethylene glycol 40002
Olive oil1
Oil macadamia nut1
Finasteridefinasteride acid0,05
Lactic acid0,05
Sodium lactate 0,1
L-ascorbate sulfate disodium0,1
Potassium salt of diapir phosphoric acid, L-ascorbic acid, dl-alpha-tocopherol0,1
Methionine4
Fish collagen0,1
Chondroitin sulfate sodium0,1
Sodium carboxymethylcellulose0,2
Polyvinyl alcohol:12
p-oxybenzoicIf necessary
PerfumeIf necessary
Purified waterUp to 100%
100,00
Example composition 27 (Wet wrap)
(Composition)Containing the s
(mass%)
Glycerin1
1,3-Butyleneglycol8

Xylitol2
Polyethylene glycol 15002
Rosemary oil0,01
Sage oil0,1
Citric acid0,02
Sodium citrate0,08
The sodium hexametaphosphate0,01
Hydroxypropyl-β(beta)-cyclodextrin0,1
Methionine, D-serine and/or D-cycloserine0,5
Extract of birch0,1
Lavender0,01
Xanthan gum0,05
Carboxyvinyl polymer 0,15
p-oxybenzoicIf necessary
Purified waterUp to 100%
100,00

An example of the composition 28 (Emulsion)
(Composition)Table of contents
(mass%)
Liquid paraffin7
Vaseline3
Decamethylcyclopentasiloxane2
Beganovic alcohol1,5
Glycerin5
Dipropyleneglycol7
Polyethylene glycol 15002
Jojoba oil1
Ezoterikova acid0,5
Stearic acid0,5
Baganova KIS the PTA 0,5
Pentaerythritol Tetra(2-ethylhexanoate)3
Cetyl-2-ethylhexanoate3
Glycerol monostearate1
Polyoxyethylene-glycerol monostearate1
The potassium hydroxide0,1
The sodium hexametaphosphate0,05
Sterillization0,05
Methionine, D-serine and/or D-cycloserine1
Royal jelly extract0,1
Yeast extract0,1
Tocopherol acetate0,1
Acetylated hyaluronate sodium0,1
Trisodium edetate0,05

4-t-Butyl-4'-methoxydibenzoylmethane 0,1
2-Ethylhexyl-parametersetname0,1
Carboxyvinyl polymer0,15
ParabenIf necessary
PerfumeIf necessary
Purified waterUp to 100%
100,00

Example of composition 29 (Emulsion)
(Composition)Table of contents
(mass%)
Dimethylpolysiloxane2
Beganovic alcohol1
Batrawy alcohol0,5
Glycerin5
1,3-Butyleneglycol7
Aritra2
Hydrogenated oil3
Squalane6
Pentaerythritol Tetra(2-ethylhexanoate)2
Polyoxyethylene glycerylmonostearate1
Polyoxyethylene glycerylmonostearate1
Methionine, D-serine and/or D-cycloserine0,3
The potassium hydroxideIf necessary
The sodium hexametaphosphate0,05
PhenoxyethanolIf necessary
Carboxyvinyl polymer0,1
Purified waterUp to 100%

100,00
An example of the composition 30 (skin Lotion)
(Composition)Table of contents
(mass%)
Ethanol5
Glycerin1
1,3-Butyleneglycol5
Polyoxyethylene-polyoxypropylene - decyltetradeceth ether1
The sodium hexametaphosphate0,03
Trimethylglycine1
Sodium salt poliasparaginovaya acid0,1
Potassium salt of diapir phosphoric acid, L-ascorbic acid, dl-alpha-tocopherol0,1
Thiotaurine0,1
D-serine and/or D-cycloserine8
Trinacria EDTA0,1
Carboxyvinyl polymer0,05
The potassium hydroxide0,02
Phenoxyethanolthe ri required
PerfumeIf necessary
Purified waterUp to 100%
100,00

An example of the composition 31 (skin Lotion)
(Composition)Table of contents
(mass%)
Ethanol5
Glycerin1
1,3-Butyleneglycol5
Polyoxyethylene-polyoxypropylene - decyltetradeceth ether0,2
The sodium hexametaphosphate0,03
Trimethylglycine1
Sodium salt poliasparaginovaya acid0,1
Potassium salt of diapir phosphoric acid, L-ascorbic acid, dl-alpha-tocopherol0,1
Thiotaurine/td> 0,1
Methionine, D-serine and/or D-cycloserine4
Trinacria EDTA0,1
Carboxyvinyl polymer0,05
The potassium hydroxide0,02
PhenoxyethanolIf necessary
PerfumeIf necessary
Purified waterUp to 100%
100,00

td align="center"> If necessary
An example of the composition 32 (skin Lotion)
(Composition)Table of contents
(mass%)
Ethanol10
Dipropyleneglycol1
Polyethylene glycol 10001
Polyoxyethylene methylglucoside1
Jojoba oilGlyceryl-three(2-ethylhexanoate)0,1
Polyoxyethylene hydrogenated castor oil0,2
Polyglycerylmethacrylate0,15
N-stearoyl-L-glutamate sodium0,1
Citric acid0,05
Sodium citrate0,2
The potassium hydroxide0,4
Dipotassium glycyrrhizinate0,1
Arginine hydrochloride0,1
2-Glucoside L-ascorbic acid2
Methionine, D-serine and/or D-cycloserine0,5
Trisodium edetate0,05
2-Ethylhexyl-parametersetname0,01
DibutylaminoethanolIf necessary
Paraben
Deep sea water3
PerfumeIf necessary
Purified waterUp to 100%
100,00

An example of the composition 33 (Stock solution for prigotovleniyanatsional drug with urea for external use)
(Composition)Table of contents
(mass%)
Ethanol15
Polyoxyethylene hydrogenated castor oil1,5
Diphenhydramine1,0
The dibucaine2,0
Tocopherol acetate0,5
Methionine, D-serine and/or D-cycloserine0,1
Ezoterikova acid0,1
1,3-Butyleneglycol 3,0
Camphor0,05
Urea20,0
Purified waterUp to 100%
100,00

An example of the composition 34 (Aerosol spray with urea)
(Composition)Table of contents
(mass%)
(Stock solution for preparation of the aerosol product with urea for external use)65,0
Dimethyl ether35,0
100,00

A method of filling for an example of the composition 34 (Aerosol spray with urea)

Stock solution for preparation of the aerosol product with urea for external use and dimethyl ether fill resistant to pressure aluminium aerosol container, the inner surface of which is coated with Teflon (trade name) with the receipt of the aerosol product.

1. Composition for reducing the damage caused by ultraviolet the new radiation, comprising one or more compounds selected from the group consisting of D-methionine and its salts.

2. The composition according to p. 1, where the composition is applied as a preparation for external use on the skin.

3. Composition under item 1 or 2, where the composition is a remedy against wrinkles.

4. Composition under item 1 or 2, where the composition is a sunscreen.

5. Composition under item 1 or 2, where the composition is used as a pharmaceutical product for skin diseases.

6. The composition according to p. 5, where a skin disease selected from the group consisting of erythema, solar dermatitis, chronic actinic dermatopathy, actinic keratosis, actinic heylita, disease favr-Rokusho, photodermatosis, photodermatitis, breakover dermatitis, photosensitive drug rash, polymorphic light eruption, light smallpox, solar urticaria, chronic photosensitive dermatitis, pigmented xeroderma, freckles, porphyria, pellagra, a disease of Hartnup, solar keratosis, dermatomyositis, flat shingles, disease Daria, red nails of pityriasis, rosacea, atopic dermatitis, chloasma, herpes simplex, lupus erythematosus, squamous cell carcinoma, basal cell carcinoma and disease Bowen.

7. The composition according to p. 5, where a pharmaceutical product for skin Soboleva what is the treatment for skin diseases.

8. The composition according to p. 6, where a pharmaceutical product for skin diseases is a treatment for skin diseases.

9. The composition according to p. 5, where a pharmaceutical product for skin diseases is a means to prevent skin diseases.

10. The composition according to p. 6, where a pharmaceutical product for skin diseases is a means to prevent skin diseases.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and medicine, namely to manufacturing drug preparations for treating allergic diseases, such as allergic rhinitis and urticaria. According to the first version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including citric acid, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, starch, lactose, magnesium stearate, and talc. According to the second version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including Pearlitol 100SD-Mannitol, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, starch, magnesium stearate, and talc. According to the third version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including sodium carboxymethyl starch, microcrystalline cellulose, colloidal silicone dioxide, and sodium sodium stearyl fumarate. According to the fourth version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including sodium carboxymethyl starch, microcrystalline cellulose, Pearlitol 100SD-Mannitol, magnesium stearate, and talc. The pharmaceutical composition is presented in the form of a film-coated tablet.

EFFECT: pharmaceutical composition according to the invention is storage-stable and releases the active substance quickly in the gastrointestinal tract.

10 cl, 9 tbl, 20 ex

FIELD: food industry.

SUBSTANCE: invention relates to nutritional compositions based on a natural extract. One proposes the application of an apple extract containing polyphenols for the manufacture of a complete nutritional composition for the reduction of symptoms of allergy caused by food in patients suffering from allergy caused by food allergens. The apple extract is enriched with polyphenols by at least 1.5 times relative to the unpurified apple extract. The composition contains 0.1% - 1 wt % of the apple extract.

EFFECT: proposed composition has no effect on the patients` sensitisation to the said allergens.

13 cl, 6 dwg

FIELD: biotechnology.

SUBSTANCE: invention is a composition having antibacterial, immunostimulating, anti-allergic and anti-inflammatory action, containing bacterial waste products useful for human body, in the form of exometabolites and fermentolysis products, characterised in that it is a culture medium of lactic acid bacteria, containing laxarane in an amount of 5-10 g/ml, caseicyne, isracydine or their mixture and lectins in an amount of 0.05-2.5 mol/l, histamine in an amount of 0.8-2.0 mmol/l and monocarboxylic fatty acid with an unbranched chain, namely, acetic acid, propionic acid, butyric acid and valeric acid - in an amount of 10-20 mg/ml.

EFFECT: expanding the range of agents having complementary antibacterial, immunomodulating, anti-allergic and anti-inflammatory action.

4 cl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of cosmetology. Described is a stable and safe antioxidant composition, which can be applied daily. In particular, described is the antioxidant composition, which contains one or more compounds, selected from the group, which consists of D-aspartic acid, its derivatives and/or its salts. The composition can be applied with the purpose of suppressing and/or relief of a skin condition. Conditions of skin can include, but are not limited by them, small wrinkles, rough skin, dry skin, skin cancer, skin allergy, skin inflammation, and light-sensitive dermatosis. The composition can be applied as a medication for the external application on the skin.

EFFECT: invention ensures an increase of the antioxidant effect of the composition.

4 cl, 5 dwg, 31 ex

FIELD: medicine.

SUBSTANCE: enterosorbent is administered in the morning in an S daily dose on an empty stomach daily for 1-3 months 2-3 hours before meals. Colonising the intestinal flora with a normal flora is ensured by daily 4-week roal administration of the liquid biocomplex Normoflorin 3 times a day in age doses; the first and second intakes involve the preparation Normoflorin L, and the third one - Normoflorin B.

EFFECT: effective treatment of allergic diseases by eliminating endogenous and exogenous toxic substances of various nature and reducing thereby body sensibilisation, providing extensive cleansing of the bowels from fermentation and putrifaction products, pathogenic and opportunistic flora, and ensuring natural immunity stimulation.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with application of extract of above-ground part/parts of oats, excluding grains, containing from 2 to 15% of flavonoids and from 0.2 to 2% of A and B avenacosides, for preparation of cosmetic and dermatological composition.

EFFECT: invention represents dermatological and cosmetic composition, containing such extract and possessing hypoallergenic properties.

8 cl, 2 ex, 2 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry and represents application of a composition, containing Bifidobacterium breve CNCM I-3865 (NCC2950) for preparation of a composition for prevention of allergic diarrhoea.

EFFECT: invention provides extension of an arsenal of means for prevention of allergic diarrhea.

7 cl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, particularly to method of treatment of dermatological allergic state. Proposed method comprises injection of efficient amount of [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-silt][7-fluorine-1-(2-metoxyethyl)-4-trifluorometoxy-1H-indol-3-il]methanon or its appropriate N-oxide, pharmaceutically acceptable salt or solvate.

EFFECT: higher efficiency.

5 cl, 1 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to an agent for preventing and/or treating an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis and asthma, which is a low-molecular polysulphated hyaluronic acid derivative.

EFFECT: obtaining a low-molecular polysulphated hyaluronic acid derivative.

15 cl, 103 dwg, 17 tbl, 55 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine and concerns preparing a fast-acting effective and safe agent for treating rhinitis. Solving the problem provides the agent for treating rhinitis, particularly allergi rhinitis containing C-type natriuretic peptide (CNP) and/or B-type natriuretic peptide (BNP) as an active ingredient.

EFFECT: invention provides the notable health improvement in rhinitis, particularly in allergic rhinitis, and besides, the therapeutic effect, ensures fast and prolonged action, and gives no local side effects.

21 cl, 7 ex, 7 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and represents a method for preparing a therapeutic radioconjugate of a specifically binding agent with a short-lived radionuclide for the delivery to pathological regions. Implementing the method involves labelling recombinant humanised mini-antibodies specific to the cancer-associated antigen HER2/neu, with the diagnostic gamma-ray radionuclide aquacarbonyl complex Tc-99m; the mini-antibodies are conjugated with human albumin; the prepared conjugate is purified and added with the chelating agent DOTA (1,4,7,10-tetraazacyclododecane tetraacetic acid) or DTPA (diethylene triamine pentaacetic acid); the prepared conjugate is labelled with the therapeutic alpha-ray radionuclides; and the produced preparation is purified.

EFFECT: producing the anti-cancer preparation possessing a low risk of the conflict with the immune system, simplifying the formulation and providing a demand for preparations with targeted agent delivery.

6 cl, 1 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to a photosensitiser for photodynamic therapy. What is declared is methyl ester 13,17-bis(N-methyl-N,N-diethylammonioethylamide) chlorine e6 ditosylate as a photosensitiser having formula: .

EFFECT: compound is stable, possesses high photobactericidal activity in vitro and high photodynamic effectiveness.

4 dwg, 2 tbl, 9 ex

FIELD: biotechnologies.

SUBSTANCE: variant immunoglobulins are provided with one or several amino acid modifications in an Fc-section, which have increased time of half-life, as well as methods of their application.

EFFECT: possibility to use compounds in medicine.

21 cl, 57 dwg, 3 tbl, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: presented inventions refers to biotechnology, and particularly to oncology and concerns an oncolytic adenovirus, using it and a pharmaceutical composition containing this adenovirus. The characterized adenovirus contains a sequence intervening into its genome and coding hyaluronidase. The enzyme expression is controlled by a promoter active in animal's cells. The presented adenovirus can be used for preparing an agent for treating cancer and pre-cancer.

EFFECT: invention enables providing higher effectiveness and selectiveness of the therapy.

20 cl, 11 dwg, 10 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula wherein each of R1 and R2 is independently selected from a group consisting of a hydrogen atom, nitro and NR6R7; R3 is C1-C8alkyl; each of R4 and R5 is independently selected from a group consisting of C1-C8alkoxy, phenoxy and phenyl(C1-C8alkylene)oxy; each of R6 and R7 is independently selected from a group consisting of a hydrogen atom, C1-C8alkyl, C(O)R8 and SO2R8;R8 is selected from a group consisting of a hydrogen atom, C1-C8alkyl, halogen-substituted C1-C8-alkyl, C1-C8-alkyl, substituted (C1-C8-alkylsubstituted amino), C1-C8-alkyl, substituted with piperidine and C1-C8-alkyl, substituted with morpholine.

EFFECT: reduced PDE4 enzyme activity and treating PDE4 enzyme mediated diseases or conditions.

21 cl, 2 tbl, 32 ex

FIELD: chemistry.

SUBSTANCE: invention relates to application of 5-amino-3-(2-aminopropyl)-[1,2,4]thiadiazole derivatives of general formula (I) as cytostatic preparations for fighting oncologic process in form of bases or pharmacologically acceptable salts. In formula (I) R1, R2 can be similar or different and independently represent hydrogen, halogen, alkyl, R3 represents alkyl, aralkyl, heteroalkyl, cycloalkyl.

EFFECT: increased efficiency of composition application.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of structural formula

possessing inhibitory activity on BTK, TEC, BMX, ITK, ErbB1, ErbB4 and/or JAK3 kinases. In formula (I-b), ring A and ring B represents phenyl; Ry represents -CN, -CF3, C1-4 aliphatic group, C1-4 halogenaliphatic group, -OR, -C(O)R or -C(O)N(R)2; each group R independently represents hydrogen or a group specified in C1-6 aliphatic group optionally containing a substitute presented by halogen, -(CH2)0-4R°, -(CH2)0-4OR°, -(CH2)0-4N(R°)2, -(CH2)0-4N(R°)C(O)OR°, -(CH2)0-4C(O)R°, -(CH2)0-4S(O)2R°, or 5-6-merous substituted or aryl ring containing 1-2 heteroatoms independently specified in nitrogen or oxygen optionally substituted by group =O, -(CH2)0-4R°, -(CH2)0-4N(R°)2 or -(CH2)0-4OR°; phenyl; 5-6-merous heterocyclic ring containing 1-2 heteroatoms independently specified in nitrogen, oxygen or sulphur optionally substituted by group -(CH2)0-4R°, -(CH2)0-4OR° or =O; or 6-merous monocyclic heteroaryl ring containing 1 nitrogen atom; W1 and W2 represent -NR2-; R2 represents hydrogen, C1-6aliphatic group or -C(O)R; m and p are independently equal to 0, 1, 2, 3 or 4; Rx is independently specified in -R, -OR, -O(CH2)qOR or halogen, wherein q=2; Rv is independently specified in -R or halogen; R1 and R° radical values are presented in the patent claim. The invention also refers to a pharmaceutical composition containing the above compounds.

EFFECT: preparing the compounds possessing the inhibitory activity on BTK, TEC, BMX, ITK, ErbB1, ErbB4 and/or JAK3 kinases.

17 cl, 25 dwg, 20 tbl, 286 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a set, containing calcium sulphate hemihydrates, pressed particles of calcium sulphate dehydrate, additionally containing one or more therapeutically, preventively and/or diagnostically active substances, and sodium-carboxymethylcellulose (Na-CMC) and a water medium, including water. The ratio R of sodium-carboxymethylcellulose and calcium sulphate in the set constitutes from 0.1 mg of sodium-carboxymethylcellulose (calculated as Na-CMC)/g of calcium sulphate to 8 mg of sodium-carboxymethylcellulose (calculated as Na-CMC)/g of calcium sulphate. When mixed, the said components of the set form a bioresorbable ceramic composition. The invention also relates to the application of the set for the treatment of a disease or condition, associated with prostate. Also claimed is a composition ready for application in the form of a paste for introduction to a patient during the time period from 5 minutes to 1 hour before hardening, obtained by mixing the components of the set. Also claimed are: a hardened composition and a method of obtaining the hardened composition or the composition ready for application.

EFFECT: control of the time of the set and composition hardening.

13 cl, 12 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents method of treating prostate cancer, which includes introduction to patient of composition, which contains degarelix lyophilisate or its pharmaceutically acceptable salt and excipient, dissolved in solvent, in initial dose 200-300 mg of degarelix in concentration 20-80 mg of degarelix per ml of solvent with the following after 14-56 days after initial dose supporting dose 320-55 mg of degarelix in concentration 50-80 mg of degarelix per ml of solvent, possibly with one or more than one following additional supporting dose 320-550 mg of degarelix in concentration 50-80 mg of degarelix per ml of solvent, introduced with interval from 56 days to 112 days between each supporting dose.

EFFECT: invention provides long release of degarelix from obtained depot of medication without increase of occurrence of side effects.

11 cl, 1 ex, 2 dwg, 4 tbl

FIELD: medicine.

SUBSTANCE: using the human placental perfusate cells in preparing a therapeutic agent for suppressing tumour cells proliferation in an individual having the tumour cells, wherein the placental perfusate cells represent a collection of nuclear cells of the placental perfusate. Using natural killer cells of CD56+, CD16- recovered from the placenta for preparing the therapeutic agent for suppressing the tumour cells proliferation in the individual having the tumour cells. Using the combined natural killer cells in preparing the therapeutic agent for suppressing the tumour cells proliferation in the individual having the tumour cells, wherein the above combined natural killer cells comprise the natural killer cells recovered from the placental perfusate, and the natural killer cells recovered from the umbilical blood, and wherein the umbilical blood is recovered from the placenta, which is used to prepare the above placental perfusate. A method for suppressing the tumour cells proliferation in vitro, involving the tumour cells contact to the human placental perfusate cells, wherein the placental perfusate cells represent the collection of the nuclear cells from the placental perfusate. The method for suppressing the tumour cells proliferation in vitro, involving the tumour cell contact to the number of the natural killer cells prepared of placental CD56+, CD16-. The method for suppressing the tumour cells proliferation in vitro, involving the tumour cells contact to the combined natural killer cells, wherein the above combined natural killer cells involve the natural killer cells recovered from the placental perfusate, and the natural killer cells recovered from the umbilical blood, and wherein the umbilical blood is recovered from the placenta, which is used for prepare the above placental perfusate. A composition applicable in suppressing the tumour cells proliferation, containing the recovered natural killer cells of CD56+, CD16-, wherein the above natural killer cells are recovered from the placental perfusate, and wherein the above natural killer cells make at least 50% cells in the composition.

EFFECT: placental perfusate cells and methods for using them enable suppressing the tumour cells proliferation effectively.

40 cl, 13 tbl, 6 ex, 11 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely ophthalmology, and aims at treating cataract. A drug preparation for treating cataract based on the active substance sodium dihydroazapentacene polysulphonate (azapentacene) is presented in the form of ophthalmic drops. Stabilising is ensured by using a borate buffer and potassium chloride, a borate buffer and sodium chloride, a phosphate buffer, a quaternary ammonium derivative, Nipaging and a preserving agent of mercury derivatives. The ingredients are used in the declared amounts.

EFFECT: using the group of inventions provides the enhanced antimicrobial properties and the reduced toxicity of the ophthalmic drops, thereby increasing the clinical effectiveness in cataract.

6 cl, 1 ex

Up!